MedAssets Inc. today announced the acquisition of MD-X Solutions, Inc, a leading provider of revenue cycle technology and services to the healthcare industry. The acquisition expands the revenue cycle offering of MedAssets to include broad solutions for Business Office outsourcing, comprehensive Denials Management software and services, HIM compliant documentation, Point-of-Service collections improvement, and "Silent PPO" Discount Recovery.

In May 2007, MedAssets also acquired Texas-based XactiMed, Inc. which offers extensive claims management solutions. The addition of MD-X and XactiMed solutions to the MedAssets Net Revenue Systems' portfolio will offer an expanded suite of technologies and services to improve the integrity of hospital revenue cycle processes so that hospitals are paid fairly for services provided, and in a timely manner.

MedAssets' push into revenue cycle management is to further deliver on its mission to improve healthcare providers' margin and cash flow by solving significant problems in revenue cycle and operating costs management - all through one business partner providing integrated customized program with guaranteed financial improvement.

MedAssets current revenue cycle offerings include chargemaster management, charge capture auditing, defensible pricing, as well as supply item file and chargemaster linkage.  The addition of these services will enhance the overall mission of MedAssets to improve cash flow and margins for healthcare providers.

MD-X, based in Mahwah, New Jersey, offers web-based tools for:

• Accounts Receivable & Denials Management Workflow Technology,
• Cash and 835 Allowance Posting, Mapping and Reconciliation,
• Concurrent Review and Case Management,
  Coding Clarification and Optimization,
• Risk Management Tracking and Reporting,
• Infectious Disease Tracking and Reporting,
• Quality and Core Measures Tracking and Reporting,
• Patient Access process improvement, and
• Dynamic Business Intelligence Reports across all MD-X applications.

MD-X was advised by the investment banking firm of VRH Partners.  Terms and conditions of the MD-X agreement are not being disclosed.